BACKGROUND: Chronic intraprostatic inflammation is suspected to play a major role in the pathogenesis of prostate cancer (PCa). Polymorphisms in interleukin-10 (IL-10), a key anti-inflammatory cytokine gene can influence immune response and immune evasion of tumor cells. Its role as an anti-metastatic molecule is also well documented. METHODS: Gene promoter polymorphisms in IL-10 (-1082 G>A and -819 C>T) was analyzed in 159 PCa patients and 259 healthy controls to investigate their potential association with susceptibility for PCa. RESULTS: Our results indicated that the heterozygous (GA) and homozygous mutant (AA) genotypes of IL-10 -1082 to be more prevalent among PCa patients in comparison to controls (GA: OR - 2.8, p = 0.011; AA: OR - 2.3, p = 0.037). More patients (92.5%) than controls (82.7%) were positive for the A allele (GA + AA: OR - 2.6, p = 0.015). We observed lower frequency of T(-819)-G(-1082) haplotype in patients without bone metastasis (4.4%, OR - 0.30, p = 0.019) in comparison to PCa patients with bone metastasis (12.6%). CONCLUSION: Our results support the emerging hypothesis that genetically determined immune activity may play a role in the pathophysiology of PCa. Our findings of high producer of IL-10 -1082 variants suggest initiation of PCa. Future studies in large cohort of different ethnicity PCa groups are warranted to establish definite associations with other cytokine gene polymorphisms.
BACKGROUND:Chronic intraprostatic inflammation is suspected to play a major role in the pathogenesis of prostate cancer (PCa). Polymorphisms in interleukin-10 (IL-10), a key anti-inflammatory cytokine gene can influence immune response and immune evasion of tumor cells. Its role as an anti-metastatic molecule is also well documented. METHODS: Gene promoter polymorphisms in IL-10 (-1082 G>A and -819 C>T) was analyzed in 159 PCa patients and 259 healthy controls to investigate their potential association with susceptibility for PCa. RESULTS: Our results indicated that the heterozygous (GA) and homozygous mutant (AA) genotypes of IL-10 -1082 to be more prevalent among PCa patients in comparison to controls (GA: OR - 2.8, p = 0.011; AA: OR - 2.3, p = 0.037). More patients (92.5%) than controls (82.7%) were positive for the A allele (GA + AA: OR - 2.6, p = 0.015). We observed lower frequency of T(-819)-G(-1082) haplotype in patients without bone metastasis (4.4%, OR - 0.30, p = 0.019) in comparison to PCa patients with bone metastasis (12.6%). CONCLUSION: Our results support the emerging hypothesis that genetically determined immune activity may play a role in the pathophysiology of PCa. Our findings of high producer of IL-10 -1082 variants suggest initiation of PCa. Future studies in large cohort of different ethnicity PCa groups are warranted to establish definite associations with other cytokine gene polymorphisms.
Authors: Tanja Eder; Ramona Mayer; Uwe Langsenlehner; Wilfried Renner; Peter Krippl; Thomas C Wascher; Karl Pummer; Karin S Kapp Journal: Eur J Cancer Date: 2006-12-19 Impact factor: 9.162
Authors: Jessica M Faupel-Badger; La Creis Renee Kidd; Demetrius Albanes; Jarmo Virtamo; Karen Woodson; Joseph A Tangrea Journal: Cancer Causes Control Date: 2007-11-13 Impact factor: 2.506
Authors: Benjamin Sredni; Merav Weil; Gennadi Khomenok; Ilana Lebenthal; Seagal Teitz; Yael Mardor; Zvi Ram; Arie Orenstein; Amir Kershenovich; Shalom Michowiz; Yan I Cohen; Zvi H Rappaport; Ilya Freidkin; Michael Albeck; Dan L Longo; Yona Kalechman Journal: Cancer Res Date: 2004-03-01 Impact factor: 12.701
Authors: L M Zheng; D M Ojcius; F Garaud; C Roth; E Maxwell; Z Li; H Rong; J Chen; X Y Wang; J J Catino; I King Journal: J Exp Med Date: 1996-08-01 Impact factor: 14.307
Authors: Jie Liu; Bao Song; Xueli Bai; Wenjian Liu; Zengjun Li; Jialin Wang; Yan Zheng; Zhehai Wang Journal: BMC Cancer Date: 2010-08-24 Impact factor: 4.430
Authors: Jian Zhou; Duo Zhang; Bin Chen; Qing Li; Lin Zhou; Fei Liu; Kuang-Yen Chou; Lei Tao; Li-Ming Lu Journal: Oncol Lett Date: 2014-02-26 Impact factor: 2.967
Authors: Dominique Z Jones; Camille Ragin; Nayla C Kidd; Rafael E Flores-Obando; Maria Jackson; Norma McFarlane-Anderson; Marshall Tulloch-Reid; Kevin S Kimbro; Lacreis R Kidd Journal: Hered Cancer Clin Pract Date: 2013-12-23 Impact factor: 2.857